ACCESSIBILITY

24/7

Headlines

13:43

EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai

21:16

Nervio appoints Dr. Richard Vogel as US CEO

19:06

Paragon’s $900M sale in limbo as Defense Ministry steps in

15:05

Full list of Israeli high-tech funding rounds in 2024

Buzz

Most popular

Daily

Weekly

EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai

Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record

Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive

The Wiz of GenAI security? “Lasso has the potential to be a once-in-a-decade company in cyber”

Israel will "experience a 'baby boom' of innovation" in 2025, says RUNI Ventures

More news

Drug

16 stories about Drug

Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros

03.06.24|Sophie Shulman

The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.

Teva is recruiting Israeli academia to help produce its next breakthrough drug

13.09.20|CTech

You reap what you sow: The pharmaceutical giant is partnering up with researchers to try and find the next Copaxone

A quantum leap In the drug development world

23.08.20|CTech

Microfluidic chips that simulate human tissue enable us to conduct medical experiments in ways that could not have been even imagined only a few years ago. Two leading Israeli researchers report from the turbulent Israeli front line of the global 'organ-on-a-chip' sector

Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company

24.12.19|Hagar Ravet

NanoGhosts turns stem cells into a drug delivery system that specifically targets cancerous tumors

Cannabis Producer Cannbit Snags THC Research Pioneer Raphael Mechoulam

04.03.19|Adi Pick

Mechoulam is a professor at the Institute for Drug Research at the Hebrew University of Jerusalem and is the subject of a 2015 movie documentary called The Scientist

Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement

03.01.19|Lilach Baumer

In December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18|Lilach Baumer

Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300

Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection

04.12.18|CTech

RedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care

Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug

29.11.18|Lilach Baumer

Called Truxima, the drug has been approved to treat several conditions of non-Hodgkin’s lymphoma

Dutch Animal Feed Company Nutreco Invests in Medical Aquafarming Startup ViAqua

05.07.18|CTech

ViAqua develops a particle-based matrix for delivering antiviral medication to shrimp

MediWound’s Pineapple-Based Burn Treatment to Treat Mustard Gas Burns

31.05.18|Dror Reich

The Nasdaq-listed, Israeli based company received the FDA’s approval to expand the use of flagship burn treatment NexoBrid to those suffering from Sulfur Mustard injuries

Israeli Cannabis Device Developer Kanabo to Set Up Marijuana Farm in Europe

27.04.18|Tofi Stoler

To carry out the plan, Kanabo is partnering with San Francisco-Based Cannabis Extract Manufacturer Constance Therapeutics

An Israeli Company Wants to Treat Tourette Syndrome With Cannabis

09.04.18|Lilach Baumer

Therapix Biosciences announced the successful completion of phase 2 clinical trial of its cannabinoid-based drug, conducted at Yale University Monday

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne

The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer

Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot

Teva Submits Potential Moneymaker Migraine Drug for FDA Approval

18.10.17|Dror Reich and Lilach Baumer

Teva’s patent for its moneymaker multiple sclerosis drug Copaxone expired last year